Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by Caption Management LLC

Caption Management LLC lowered its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 82.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,998 shares of the company's stock after selling 95,674 shares during the quarter. Caption Management LLC's holdings in Ginkgo Bioworks were worth $196,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bank of America Corp DE increased its holdings in Ginkgo Bioworks by 780.6% in the fourth quarter. Bank of America Corp DE now owns 3,764,455 shares of the company's stock valued at $36,967,000 after buying an additional 3,336,964 shares during the last quarter. Forbes J M & Co. LLP increased its holdings in shares of Ginkgo Bioworks by 461.4% in the 4th quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company's stock valued at $6,891,000 after acquiring an additional 576,732 shares during the last quarter. Erste Asset Management GmbH raised its position in shares of Ginkgo Bioworks by 47.9% during the 4th quarter. Erste Asset Management GmbH now owns 739,332 shares of the company's stock worth $6,979,000 after acquiring an additional 239,332 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in Ginkgo Bioworks during the fourth quarter worth approximately $1,796,000. Finally, BNP Paribas Financial Markets lifted its stake in Ginkgo Bioworks by 80.6% during the fourth quarter. BNP Paribas Financial Markets now owns 285,111 shares of the company's stock worth $2,800,000 after purchasing an additional 127,249 shares during the last quarter. 78.63% of the stock is currently owned by hedge funds and other institutional investors.

Ginkgo Bioworks Stock Down 1.5 %

Ginkgo Bioworks stock traded down $0.12 during mid-day trading on Friday, hitting $7.75. The company had a trading volume of 1,025,844 shares, compared to its average volume of 1,473,866. Ginkgo Bioworks Holdings, Inc. has a 1 year low of $5.00 and a 1 year high of $38.58. The business has a fifty day moving average of $7.13 and a 200 day moving average of $9.07. The stock has a market cap of $449.76 million, a price-to-earnings ratio of -0.59 and a beta of 1.29.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.35). The company had revenue of $48.32 million during the quarter, compared to analysts' expectations of $38.70 million. Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. Equities analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.